Ramesh Subrahmanian is leaving Stryker Corporation.
Stryker Restructures – Subrahmanian Leaves
1 min read Premium comments
Effective December 31, 2015, Subrahmanian will no longer serve as Group President, International, “as a consequence of a restructuring of the company’s international group, ” stated a company September 17, 2015 SEC regulatory filing.
He’ll stay on in an advisory role for three months following his departure and continue to receive his current compensation and benefits.
In addition, the regulatory filing said he will be eligible for an incentive payment of $99, 187.50 for the advisory period and will receive a severance payment in the amount of $396, 750.00 payable in 18 semi-monthly installments during the last nine months of 2016 and a lump sum payment of $275, 000.00 on or before March 15, 2016.
Subrahmanian has been on assignment in Singapore and will also be entitled to receive relocation benefits.
Former Stryker CEO, Stephen MacMillan hired Subrahabnian away from Merck & Co. in 2011 to beef up less than stellar international sales. He had spent 23 years in the pharmaceutical industry where he held various senior level jobs. In addition to Merck, he worked for Sanofi-Aventis and Hoechst Marion Rousel Ltd.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.